Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Value of magnetic resonance spectroscopy (MSR) and dynamic contrast-enhanced magnetic resonance (DCEMR) imaging for the characterization of high-grade prostatic intraepithelial neoplasia (HGPIN) foci.
Sciarra A, Panebianco V, Salciccia S, Gentilucci A, Alfarone A, Dimare L, Lisi D, Catturino S, Di Pierro G, Von Heland M, Ciccariello M, Passariello R, Gentile V. Sciarra A, et al. Among authors: alfarone a. Urol Oncol. 2011 Nov-Dec;29(6):634-40. doi: 10.1016/j.urolonc.2009.07.033. Epub 2009 Nov 13. Urol Oncol. 2011. PMID: 19914107
Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy.
Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D, Gentilucci A, Alfarone A, Bernardo S, Passariello R, Gentile V. Sciarra A, et al. Among authors: alfarone a. Clin Cancer Res. 2010 Mar 15;16(6):1875-83. doi: 10.1158/1078-0432.CCR-09-2195. Epub 2010 Mar 2. Clin Cancer Res. 2010. PMID: 20197480 Clinical Trial.
Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR).
Sciarra A, Panebianco V, Salciccia S, Lisi D, Alfarone A, Gentilucci A, Parente U, Cattarino S, Passariello R, Gentile V. Sciarra A, et al. Among authors: alfarone a. Urol Oncol. 2012 Sep;30(5):614-9. doi: 10.1016/j.urolonc.2010.09.006. Epub 2011 Mar 10. Urol Oncol. 2012. PMID: 21396849 Clinical Trial.
Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer.
Alfarone A, Panebianco V, Schillaci O, Salciccia S, Cattarino S, Mariotti G, Gentilucci A, Von Heland M, Passariello R, Gentile V, Sciarra A. Alfarone A, et al. Crit Rev Oncol Hematol. 2012 Oct;84(1):109-21. doi: 10.1016/j.critrevonc.2012.01.006. Epub 2012 Mar 7. Crit Rev Oncol Hematol. 2012. PMID: 22401991 Review.
Use of 3D T2-weighted MR sequences for the assessment of neurovascular bundle changes after nerve-sparing radical retropubic prostatectomy (RRP): a potential diagnostic tool for optimal management of erectile dysfunction after RRP.
Sciarra A, Panebianco V, Salciccia S, Alfarone A, Gentilucci A, Lisi D, Passariello R, Gentile V. Sciarra A, et al. Among authors: alfarone a. J Sex Med. 2009 May;6(5):1430-7. doi: 10.1111/j.1743-6109.2009.01241.x. J Sex Med. 2009. PMID: 19473289
Update on screening in prostate cancer based on recent clinical trials.
Sciarra A, Cattarino S, Gentilucci A, Salciccia S, Alfarone A, Mariotti G, Innocenzi M, Gentile V. Sciarra A, et al. Among authors: alfarone a. Rev Recent Clin Trials. 2011 Jan;6(1):7-15. doi: 10.2174/157488711793980165. Rev Recent Clin Trials. 2011. PMID: 20868347 Review.
21 results